MGNX Macrogenics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MGNX

Price (delayed)

$4.1

Market cap

$261.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.22

Enterprise value

$360.5M

?
Relative Growth: Rel. Growth: 73
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 44

MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product ...

Highlights
The EPS has soared by 80% from the previous quarter and by 61% YoY
MGNX's net income has soared by 79% QoQ and by 60% YoY
Macrogenics's equity has surged by 102% QoQ but it has decreased by 8% YoY
The quick ratio has soared by 70% QoQ but it fell by 40% YoY
MGNX's debt has surged by 103% since the previous quarter and by 98% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.macrogenics.com
Peers: XNCR GILD MRK PFE

Key stats

What are the main financial stats of MGNX

MGNX stock price

How has the Macrogenics stock price performed over time
Intraday
0.74%
1 week
-2.84%
1 month
-9.69%
1 year
184.72%
YTD
154.66%
QTD
-11.26%

Financial performance

How have Macrogenics's revenue and profit performed over time
Revenue
$167.67M
Gross profit
$136.44M
Operating income
-$40.75M
Net income
-$14.59M
Gross margin
81.4%
Net margin
-8.7%
MGNX's net margin has surged by 82% since the previous quarter and by 64% year-on-year
MGNX's net income has soared by 79% QoQ and by 60% YoY
Macrogenics's operating margin has surged by 57% YoY and by 51% QoQ
The company's operating income has surged by 52% YoY and by 42% QoQ

Price vs fundamentals

How does MGNX's price correlate with its fundamentals

Growth

What is Macrogenics's growth rate over time

Valuation

What is Macrogenics stock price valuation
P/E
N/A
P/B
6.08
P/S
1.56
EV/EBIT
235.62
EV/EBITDA
39.53
EV/Sales
2.15
The EPS has soared by 80% from the previous quarter and by 61% YoY
Macrogenics's equity has surged by 102% QoQ but it has decreased by 8% YoY
The P/B is 79% above the 5-year quarterly average of 3.4 and 29% above the last 4 quarters average of 4.7
The price to sales (P/S) is 66% lower than the 5-year quarterly average of 4.6 but 30% higher than the last 4 quarters average of 1.2
The revenue has increased by 18% QoQ and by 12% YoY

Efficiency

How efficient is Macrogenics business performance
The ROS has soared by 104% YoY and by 102% from the previous quarter
MGNX's ROIC has soared by 102% QoQ and by 102% YoY
MGNX's ROA has soared by 81% from the previous quarter and by 63% YoY
MGNX's return on equity has surged by 79% since the previous quarter and by 22% year-on-year

Dividends

What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGNX.

Financial health

How did Macrogenics financials performed over time
The total assets is 14% more than the total liabilities
The quick ratio has soared by 70% QoQ but it fell by 40% YoY
The total assets has soared by 59% from the previous quarter and by 41% YoY
The debt to equity has surged by 115% year-on-year
MGNX's debt has surged by 103% since the previous quarter and by 98% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.